Rintaro Hashizume

This study identifies CPA4 as a YAP-TEAD-driven effector in NF2-deficient meningioma, showing its role in tumor growth and sensitivity to TEAD inhibitors.

The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

The paper shows BMP4 reduces H3K4me3 levels in human neural stem cells by downregulating SETD1A and WDR82, leading to decreased proliferation and increased differentiation.